Ozempic (semaglutide) mimics a natural gut hormone called GLP-1 to lower blood sugar in multiple ways at once: boosting insulin when glucose is high, dialing back a hormone that raises blood sugar, and slowing how fast food leaves your stomach. It’s given as a once-weekly injection and typically lowers A1C by 0.5 to 1.0 percentage points more than other common diabetes medications.
How It Mimics a Gut Hormone
After you eat, your intestines release a hormone called GLP-1 that signals your pancreas to produce insulin. The problem is that natural GLP-1 breaks down in your body within minutes. Ozempic is a synthetic version engineered to last much longer, which is why a single injection covers an entire week.
Once injected, semaglutide binds to the same receptors that natural GLP-1 uses, but it stays active for days instead of minutes. This sustained activity keeps the signaling “on” in a way your body’s own hormone can’t achieve, particularly in people with type 2 diabetes whose GLP-1 response is often blunted.
Three Ways It Lowers Blood Sugar
Ozempic doesn’t work through a single pathway. It targets blood sugar from three directions simultaneously.
Glucose-dependent insulin release. When your blood sugar rises after a meal, Ozempic amplifies the signal telling your pancreas to release insulin. Crucially, this only happens when glucose is elevated. When blood sugar is normal or low, the drug largely stops stimulating insulin, which is why it carries a much lower risk of dangerous blood sugar drops compared to older diabetes medications like sulfonylureas.
Glucagon suppression. Your pancreas also produces glucagon, a hormone that tells your liver to dump stored sugar into your bloodstream. In type 2 diabetes, glucagon is often overactive, pushing blood sugar higher even when it’s already elevated. Ozempic quiets that glucagon signal after meals, reducing the liver’s unnecessary sugar output.
Slower stomach emptying. Ozempic significantly slows the rate at which food moves from your stomach into your small intestine, where nutrients get absorbed. In one study, the time it took for half a meal to leave the stomach increased from about 118 minutes to 171 minutes. Four hours after eating, people on semaglutide still had 37% of their meal in their stomach, compared to essentially zero in the placebo group. This means glucose enters your bloodstream more gradually, preventing the sharp post-meal spikes that are a hallmark of type 2 diabetes.
What the Clinical Results Look Like
Across the SUSTAIN trial program, the 0.5 mg dose reduced A1C by an additional 0.32 to 0.79 percentage points beyond what comparator medications achieved. The 1.0 mg dose performed even better, with reductions of 0.38 to 1.07 percentage points beyond comparators. These are differences on top of the effect of background medications like metformin, meaning the total A1C drop for most people is substantial.
Weight loss is a consistent secondary benefit. The same slowed digestion that blunts glucose spikes also makes people feel full longer, leading to reduced calorie intake without deliberate dieting in many cases.
Benefits Beyond Blood Sugar
One of the reasons Ozempic has become a preferred treatment is what it does for the cardiovascular system. A combined analysis of two large cardiovascular outcomes trials found that semaglutide reduced the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) by 24% compared to placebo in people with type 2 diabetes. That’s a meaningful reduction for a population where heart disease is the leading cause of death.
Kidney protection has also emerged as a significant benefit. The FLOW trial, published in 2024, showed that semaglutide reduced the risk of serious kidney outcomes by 24%. That composite included kidney failure requiring dialysis or transplant, a 50% decline in kidney function, or death from kidney or cardiovascular causes. Cardiovascular death alone was reduced by 29%. These results led to updated guidelines recommending GLP-1 medications for people with type 2 diabetes and chronic kidney disease.
Where It Fits in Treatment Guidelines
The American Diabetes Association’s 2025 Standards of Care place GLP-1 medications like Ozempic in a prominent role. For anyone with type 2 diabetes who has cardiovascular disease or is at high risk for it, guidelines recommend including a GLP-1 medication regardless of current A1C levels. The same applies to people with chronic kidney disease, where a GLP-1 option is recommended both for blood sugar management and to slow kidney decline.
For people with type 2 diabetes who don’t produce enough insulin on their own, guidelines now prefer a GLP-1 medication over starting insulin. If insulin is still needed, combining it with a GLP-1 medication is recommended because the combination improves blood sugar control while reducing the weight gain and hypoglycemia risk that often come with insulin alone. One important note: Ozempic should not be taken alongside DPP-4 inhibitors (medications like sitagliptin or saxagliptin), because both drugs work on the same pathway and combining them adds no extra benefit.
Dosing and What to Expect
Ozempic is injected once a week, on the same day each week, at any time of day, with or without food. The starting dose of 0.25 mg is not a treatment dose. It exists solely to let your body adjust and reduce side effects. After four weeks, the dose increases to 0.5 mg, which is the first therapeutic level. From there, your prescriber may increase to 1.0 mg or eventually 2.0 mg (the maximum) depending on how your blood sugar responds and how well you tolerate the medication.
For people with chronic kidney disease, guidelines suggest increasing to 1.0 mg after at least four weeks on the 0.5 mg dose.
Common Side Effects
The most frequent side effects are gastrointestinal: nausea, vomiting, and diarrhea. These affect more than 5% of people taking Ozempic in clinical trials and are directly related to the slowed stomach emptying that also helps control blood sugar. Most people find that nausea is worst during the first few weeks or after a dose increase, then fades as the body adjusts. The gradual dose escalation exists specifically to minimize this.
Ozempic is not recommended for people with severe gastroparesis, a condition where the stomach already empties too slowly. It is contraindicated entirely in anyone with a personal or family history of medullary thyroid carcinoma or a condition called multiple endocrine neoplasia syndrome type 2. In animal studies, semaglutide caused thyroid tumors, though it remains unclear whether this risk translates to humans.